Genetic predictors of severe skin toxicity in stage III colon cancer patients treated with cetuximab: NCCTG N0147 (Alliance)

BACKGROUND: Cetuximab, an epidermal growth factor receptor inhibitor used to treat multiple cancer types including colon cancer, causes severe skin toxicity in 5-20% of patients, leading to decreased quality of life and treatment delays. Our understanding of which patients have an increased risk of...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Epidemiol Biomarkers Prev
Autors principals: Labadie, Julia D., Hua, Xinwei, Harrison, Tabitha A., Banbury, Barbara L., Huyghe, Jeroen R., Sun, Wei, Shi, Qian, Yothers, Greg, Alberts, Steven R., Sinicrope, Frank A., Goldberg, Richard M., George, Thomas J., Penney, Kathryn L., Phipps, Amanda I., Cohen, Stacey A., Peters, Ulrike, Chan, Andrew T., Newcomb, Polly A.
Format: Artigo
Idioma:Inglês
Publicat: 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7909617/
https://ncbi.nlm.nih.gov/pubmed/33203692
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1055-9965.EPI-20-1274
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars